

NeuroNEXT Network

Standard Operating Procedure (SOP)




Routine Monitoring Visits

Version 3.0


SOP NN SS 403

Originators: NeuroNEXT CCC and DCC Personnel

Reviewed and Approved by:

Signature and Date: <small>DocuSigned by Christopher Coffey</small>  I approve this document 14-Feb-2023 12:31:51 PM PST <small>C68AC8DD80334CF982AED1200765F147</small> 14-Feb-2023
Name and Title: Christopher S. Coffey, PhD (DCC Principal Investigator)
Signature and Date: <small>DocuSigned by Merit Cudkowicz</small>  I approve this document 14-Feb-2023 9:59:49 AM EST <small>9F8FE4180E504C6AB0A67B835E80C644</small> 14-Feb-2023
Name and Title: Merit E. Cudkowicz, MD MSc (CCC Principal Investigator)
Signature and Date: <small>DocuSigned by Marianne Chase</small>  I approve this document 14-Feb-2023 11:32:57 AM EST <small>58FE690F6BCA4F2390E3DA15BCE3F578</small> 14-Feb-2023
Name and Title: Marianne Chase, BA (CCC Senior Director of Clinical Trials Operations)

Signature and Date:

DocuSigned by DIXIE ECKLUND
 | I approve this document
15-Feb-2023 | 10:53:06 AM PST
7006AF622EFC40B6A067A08EC02591B6

15-Feb-2023

Name and Title: Dixie J. Ecklund, RN MSN MBA (DCC Associate Director)

Signature and Date:

DocuSigned by Stacey Grabert
 | I approve this document
22-Feb-2023 | 11:26:30 AM EST
60CC52B0747A44E6B2208D8D880698C0

22-Feb-2023

Name and Title: Stacey Grabert, Pharm.D, MS, (CCC Director of Quality Assurance)

Signature and Date:

DocuSigned by Joan Ohayon
 | I approve this document
14-Feb-2023 | 9:35:40 AM PST
72C6AAF8CC4485582ACA0700072901A

14-Feb-2023

Name and Title: Joan Ohayon, RN, MSN, CRNP, MSCN (NINDS, NeuroNEXT Program Official)

**NEURONEXT NETWORK STANDARD OPERATING PROCEDURE FOR
ROUTINE MONITORING VISITS**

1. POLICY

This SOP describes procedures regarding scheduling, frequency, preparing for, and conducting a routine monitoring, remote or on- site visit for NeuroNEXT clinical trials. Routine monitoring visits for Clinical Study Sites (CSS) will be scheduled according to the requirements of the approved study monitoring plan. Guidelines for scheduling monitoring visits for each NeuroNEXT CSS will be determined by the NeuroNEXT Data Coordinating Center (DCC) in consultation with the Clinical Coordinating Center (CCC) and according to the stage of development and complexity of the studies at the CSS, the rates of subject accrual, and other factors.

These visits are conducted for routine monitoring only and are intended to ensure that the protocols and applicable regulatory requirements are being followed, that subjects' rights and safety are being protected, and to confirm data integrity and quality.

The objectives of routine monitoring visits are to:

- document and report on clinical study progress;
- document that the protocols and associated forms are current;
- update the site team of any changes in study conduct/documentation;
- ensure that the PPI/Sponsor requirements and investigator obligations are met;
- ensure continued acceptability of the investigator, site team and facility;
- obtain and review current clinical data, reports, and source documents;
- ensure adequate investigational product inventory and accountability, if applicable.

Activities conducted during the preparation for a monitoring visit include reviews of study documents, data queries, data reports, previous monitoring reports, and supplies of study materials (if applicable).

During the monitoring visit, the monitor performs the following activities:

- assesses the overall status of the study, staff, and facilities (if on-site) to determine whether the study is being conducted per protocol and in compliance with regulatory requirements;
- conducts a review of CRFs and source documentation to verify all adverse event documentation;
- conducts a review of CRFs and source documentation for primary and secondary study outcomes.
- conducts a review of additional study data or procedures, as necessary.
- verifies the presence of all essential documents and records related to investigational products and clinical supplies (if applicable); and
- determines if protocol violations have occurred and, if so, are documented properly.

After the monitoring visit, the monitor documents the results of the visit and completes a post-visit monitoring letter that conveys any issues discovered during the visit and the need for data corrections, if appropriate.

2. SCOPE

This SOP has been developed to be in alignment with federal regulations and Good Clinical Practices (GCP) as set forth in the 2016 Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). The policies and procedures described in this SOP apply to the NeuroNEXT CCC and DCC within the context of their oversight and advisory roles for the NeuroNEXT Network, and to all NeuroNEXT investigators, staff, subcontractors, or other entities associated with the NeuroNEXT Network who manage, oversee, and conduct research regulated by FDA and/or applicable review committees.

3. ROLES AND RESPONSIBILITIES

The DCC is responsible for designating a trained and qualified member of the research team to serve as study Monitor. The DCC Monitor is responsible for preparing for, conducting, and documenting all monitoring visits.

The responsibility to conduct any or all of these activities can be delegated at the discretion of the Sponsor/PPI to the DCC, or to subcontractors of the DCC where applicable. Those individuals and entities also take on responsibility for meeting regulatory requirements on behalf of the Sponsor, but the Sponsor has the ultimate responsibility, and must therefore supervise those delegated activities effectively.

4. APPLICABLE REGULATIONS AND GUIDELINES

21 CFR 312.53	Selecting Investigators and Monitors
21 CFR 312.56	Review of Ongoing Investigations
ICH E6, 4.1	Investigator's Qualifications and Agreement
ICH E6, 5.5	Trial Management, Data Handling and Record Keeping
ICH E6, 5.18	Monitoring
FDA	Guidance for Industry: Oversight of Clinical Investigations – A Risk-Based Approach to Monitoring (August 2013)

5. REFERENCES TO OTHER APPLICABLE SOPS

NN RA 202	Trial Master File Maintenance
NN RA 203	Site Regulatory File Maintenance
NN SS 402	Site Initiation Visits and Site Training
NN SS 404	Site Performance Monitoring
NN PM 501	Communication
NN PM 504	Investigational Site Staff Training
NN PM 505	Investigational Product Management
NN SM 602	Single Institutional Review Board Reporting
NN SM 603	Subject Eligibility and Enrollment
NN DM 1001	Clinical Data Management

6. ATTACHMENTS AND REFERENCES

NN SS 403 - A	Document History
---------------	------------------

7. TERMS AND ABBREVIATIONS

The following terms and abbreviations are used in this document:

AE	Adverse Events
CCC	Clinical Coordinating Center at Massachusetts General Hospital
SIRB	Single Institutional Review Board
CRF	Case Report Forms that are completed for each study subject at the sites
CSS	Clinical Study Site(s)
DCC	Data Coordinating Center at The University of Iowa
FDA	U.S. Food and Drug Administration
ICH	International Council for Harmonisation

PPI Protocol Principal Investigator
 RMF Regulatory Master File

8. SPECIFIC PROCEDURES

A. Scheduling/Frequency of Monitoring Visits

#	Who	Task	Attachment/Reference	Related SOP
1.	DCC Lead Coordinator, DCC Monitor	Determine the type of monitoring visits required for each study; remote, on-site, or both.		
2.	DCC Lead Coordinator, DCC Monitor	Develop a monitoring plan that includes conducting a minimum of one monitoring visit (on-site or remote) at each CSS with an ongoing protocol per year.		
3.	DCC Monitor	Review study reports to determine when to schedule CSS visits according to the monitoring plan.		
4.	DCC Monitor	Conduct unscheduled or more frequent monitoring visits to CSS as needed.		
5.	DCC Monitor	Contact the investigator or designee and study coordinator regarding scheduling and conducting monitoring visits.		NN PM 501
6.	DCC Monitor	Confirm date and logistics of the monitoring visit in writing and provide the investigator with a list of source documents and records (e.g., medical records, laboratory records, etc.) to be reviewed. If the visit is remote, provide information and link for secure upload of source documents.		NN PM 501
7.	DCC Monitor	Create a monitoring report to track CSS visits.		

B. Preparing for a Monitoring Visit

#	Who	Task	Attachment/Reference	Related SOP
1.	DCC Monitor or CCC Project Manager	Review the Delegation of Responsibility (DOR) logs for site staffs, if applicable, prior to the monitoring visit.		NN RA 202
2.	DCC Monitor	Review the current version of the clinical protocols and informed consent forms prior to the monitoring visit, if applicable.		
3.	DCC Monitor	Review the data reports and data queries for any data received to date for each study.		
4.	DCC Monitor	Review previous monitoring reports for any outstanding items that must be addressed prior to, or during, the next scheduled visit.		
5.	DCC Monitor and CCC Project Manager	Determine the CSS inventory of study supplies, including forms or other relevant materials and investigational products (if applicable). Arrange to provide additional items as necessary.		

C. Conducting a Monitoring Visit

1. Overall Study Status

#	Who	Task	Attachment/ Reference	Related SOP
1.	DCC Monitor	If on-site, verify that the CSS subject files for the study contain all required documents and records, and that they are accurate, complete, and current.		NN RA 203
2.	DCC Monitor	If requested by the CCC, confirm with the investigator that the CSS routinely files and forwards essential and required information to other required parties (e.g. SIRB) appropriately.	RA 203-B	NN SM 602
3.	DCC Lead Coordinator and DCC Monitor	Assess subject enrollment rates and examine unexpectedly high or low recruitment.		NN SM 603
4.	DCC Monitor	Review study screening and enrollment logs for information on subjects who failed to meet inclusion criteria, did not give informed consent, or withdrew from the study for any reason.		NN SM 603
5.	DCC Monitor	Confirm eligibility of enrolled subjects.		
6.	DCC Monitor	Confirm that all subjects have signed the correct version(s) of the informed consent form.		
7.	DCC Monitor	Evaluate status of follow-up plans and visits for subjects and identify problems.		
8.	DCC Monitor	Confirm that safety and efficacy assessments are conducted per the study protocols.		
9.	DCC Monitor	Verify that all specimens for protocol-specific laboratory studies are being stored and forwarded properly and that specimen preparation documentation is maintained.		NN PM 505
10.	DCC Monitor	Meet with investigator and key staff during on-site visits, or by zoom for remote visits to discuss any scientific or administrative problems and possible solutions.		

2. CRF Review

#	Who	Task	Attachment/ Reference	Related SOP
1.	DCC Monitor	Verify that CRFs ¹ are being completed in a timely manner and per protocol requirements.		NN DM 1001
2.	DCC Monitor	Review the CRFs scheduled for review (as outlined in the monitoring plan) to ensure that they are complete, legible, consistent with protocol specifications, and signed by the appropriate site personnel.		
3.	DCC Monitor	For randomized studies, verify that the randomization procedures are being carried out per the study protocols.		

#	Who	Task	Attachment/ Reference	Related SOP
4.	DCC Monitor	Evaluate allocation of investigational products, if applicable.		NN PM 505
5.	DCC Monitor	Check data in the CRFs scheduled for review against source documents to assess accuracy and completeness of the information.		
6.	DCC Monitor	Review and address omissions and queries, and ensure that corrections to the CRFs are properly completed at the end of the visit or agree with CSS staff on a plan to complete corrections post-visit.		
7.	DCC Monitor	Tabulate changes and corrections for updating the study databases.		
8.	DCC Monitor	Assess whether all adverse events (AEs) have been documented and reported as specified by the protocols, and that other relevant regulatory procedures have been followed.		NN SM 602
Note: 1 CRF(s) can be paper or electronic.				

3. Investigational Products and Other Clinical Supplies (if applicable)

#	Who	Task	Attachment	Related SOP
1.	DCC Monitor	Determine how often monitoring will occur and if the monitoring visit will be conducted on-site or remotely.		NN PM 505
2.	DCC Monitor	If visit is conducted on-site conduct the following: <ul style="list-style-type: none"> a. Verify storage of investigational products and other clinical supplies. b. Assess investigational product dispensing and accountability records. c. Examine storage freezers and other storage equipment to confirm they are appropriate for the clinical protocol's requirements, and that calibration and temperature logs are maintained in the CSS study files. 		NN PM 505
3.	DCC Monitor	If visit is conducted remotely, contact the site pharmacist to set up a remote visit and request the following to monitor: <ul style="list-style-type: none"> a. Access to investigational product dispensing and accountability records. b. Shipping records and receipts c. Temperature logs, if applicable. 		
66	DCC Monitor	Complete a post visit letter detailing findings and any pending items. Letter should be sent to the site study pharmacist, CSSPI, NNPI, NNC, and CSSC.		

4. Staff and Facilities

#	Who	Task	Attachment	Related SOP
1.	DCC Monitor	Confirm each study investigator's control of the study and assess his/her ongoing participation and any responsibility delegations not previously reported.		
2.		Assess the ongoing suitability of facilities and staff for conducting the study.		
3.		Note and record any changes in staff or facility not previously reported.		NN SS 402
4.		If applicable, discuss scheduling additional study training for new staff.		NN PM 504

5. Documents

#	Who	Task	Attachment	Related SOP
1.	DCC Monitor	Review Delegation of Responsibility logs for each site staff to confirm staff are approved and delegated to perform study activities.		NN RA 203

6. Protocol Violations

#	Who	Task	Attachment	Related SOP
2.	DCC Monitor	Note whether the records show any evidence that protocol violations have occurred, and record the nature of these violations.		
3.	DCC Monitor	For each study, review any issues related to study conduct or other incidents of noncompliance with the investigator and other key study personnel, and document the issues on the monitoring report.		
4.	DCC Monitor and CCC Project Manager	If needed, an ongoing process of counseling, re-education and re-training shall be undertaken by the appropriate Study staff to ensure trial CSS compliance.		NN SS 404

7. Documenting Results of Monitoring Visits

#	Who	Task	Attachment	Related SOP
1.	DCC	Document all on-site visits by monitors and other authorized parties on a Site Visit Log.		NN SS 402
2.		Document the outcome of all scheduled and unscheduled monitoring visits.		
3.		Complete a post visit monitoring letter for each study. The letter may include and address the following, if applicable: <ul style="list-style-type: none"> • Protocol compliance • Subject enrollment and study timelines • Review of regulatory documents and findings 		

#	Who	Task	Attachment	Related SOP
		<ul style="list-style-type: none"> • Review of subject files and source documents • Investigational product accountability • Data corrections • Pending issues and action items 		
4.		Significant site issues should be communicated and escalated to the study team, PPI, and site intervention team.		NN SS 406 NN SS 404
5.		Provide the CCC with copies of the completed Monitoring Visit Checklists, Reports, and the CSS post-visit monitoring letters for review.		
6.		Provide the NNPI, NNC, CSS Study PI and Study Coordinator with the post-visit monitoring letter(s).		
7.		Instruct site to place the post-visit monitoring letter(s) in the study regulatory binder.		
8.	CCC Project Manager	File the completed reports and letters in the appropriate site files in the TMF.		NN RA 203

Certificate Of Completion

Envelope Id: A41C76D0B1C2491C86DB213C7698463D Status: Completed
Subject: Complete with DocuSign: NN SS 403 Routine Monitoring Visits v3.0.docx
Source Envelope:
Document Pages: 9 Signatures: 6 Envelope Originator:
Certificate Pages: 6 Initials: 0 Tania Leeder
AutoNav: Enabled TLEEDER@PARTNERS.ORG
Envelopeld Stamping: Disabled IP Address: 73.123.188.5
Time Zone: (UTC-05:00) Eastern Time (US & Canada)

Record Tracking

Status: Original Holder: Tania Leeder Location: DocuSign
2/14/2023 9:47:11 AM TLEEDER@PARTNERS.ORG

Signer Events

Christopher Coffey
christopher-coffey@uiowa.edu
Security Level: Email, Account Authentication (Required)

Signature

Christopher Coffey

Timestamp

Sent: 2/14/2023 9:48:51 AM
Viewed: 2/14/2023 3:31:31 PM
Signed: 2/14/2023 3:31:54 PM

Signature Adoption: Pre-selected Style
Signature ID:
C68AC8DD-8033-4CF9-82AE-D1200765F147
Using IP Address: 128.255.113.139

With Signing Authentication via DocuSign password
With Signing Reasons (on each tab):
I approve this document

Electronic Record and Signature Disclosure:
Accepted: 2/14/2023 3:31:31 PM
ID: db3847e9-c45d-4513-93bb-c3677ab7507b

DIXIE ECKLUND
dixie-ecklund@uiowa.edu
Security Level: Email, Account Authentication (Required), Login with SSO

DocuSigned by DIXIE ECKLUND
I approve this document
15-Feb-2023 | 10:53:06 AM PST
7006AF622EFC40B6A067A08EC02591B6

Sent: 2/14/2023 9:48:52 AM
Viewed: 2/15/2023 1:51:33 PM
Signed: 2/15/2023 1:53:10 PM

Signature Adoption: Drawn on Device
Signature ID:
7006AF62-2EFC-40B6-A067-A08EC02591B6
Using IP Address: 128.255.112.230

With Signing Authentication via DocuSign password
With Signing Reasons (on each tab):
I approve this document

Electronic Record and Signature Disclosure:
Accepted: 2/15/2023 1:51:33 PM
ID: 0febeea4-0ef4-447f-bb48-60254f3ff624

Signer Events**Signature****Timestamp**

Joan Ohayon
 ohayonj@ninds.nih.gov
 Security Level: Email, Account Authentication
 (Required)

Joan Ohayon

Sent: 2/14/2023 9:48:53 AM
 Viewed: 2/14/2023 12:35:14 PM
 Signed: 2/14/2023 12:35:43 PM

Signature Adoption: Pre-selected Style
 Signature ID:
 72C6AAFD-8CC4-4855-82AC-A0700072901A
 Using IP Address: 156.40.137.188

With Signing Authentication via DocuSign password
 With Signing Reasons (on each tab):
 I approve this document

Electronic Record and Signature Disclosure:
 Accepted: 2/13/2023 2:03:22 PM
 ID: 385a0a53-0f0c-4395-88f6-d5700c36e050

Marianne Chase
 MCHASE@mgh.harvard.edu
 Sr Director, Clinical Trial Operations
 Insight OBO The Massachusetts General Hospital
 Security Level: Email, Account Authentication
 (Required)

Marianne Chase


Sent: 2/14/2023 9:48:52 AM
 Viewed: 2/14/2023 11:32:36 AM
 Signed: 2/14/2023 11:33:04 AM

Signature Adoption: Pre-selected Style
 Signature ID:
 58FE690F-6BCA-4F23-90E3-DA15BCE3F578
 Using IP Address: 73.114.253.109

With Signing Authentication via DocuSign password
 With Signing Reasons (on each tab):
 I approve this document

Electronic Record and Signature Disclosure:
 Not Offered via DocuSign

Merit Cudkowicz
 cudkowicz.merit@mgh.harvard.edu
 Chief of Neurology
 Security Level: Email, Account Authentication
 (Required), Logged in

DocuSigned by Merit Cudkowicz

 I approve this document
 14-Feb-2023 | 9:59:49 AM EST
 9F8FE4180E504C6AB0A67B835E80C644


Sent: 2/14/2023 9:48:52 AM
 Viewed: 2/14/2023 9:59:14 AM
 Signed: 2/14/2023 9:59:52 AM

Signature Adoption: Pre-selected Style
 Signature ID:
 9F8FE418-0E50-4C6A-B0A6-7B835E80C644
 Using IP Address: 50.216.106.4

With Signing Authentication via DocuSign password
 With Signing Reasons (on each tab):
 I approve this document

Electronic Record and Signature Disclosure:
 Accepted: 2/14/2023 9:59:14 AM
 ID: 798d43ba-2e45-4165-a28c-7ab907f862f8

Signer Events	Signature	Timestamp
---------------	-----------	-----------

Stacey Grabert sgrabert@mgh.harvard.edu Director QA Stacey Grabert Security Level: Email, Account Authentication (Required)	 Signature Adoption: Pre-selected Style Signature ID: 60CC52B0-747A-44E6-B220-8D8D880698C0 Using IP Address: 132.183.56.49 With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document	Sent: 2/14/2023 9:48:53 AM Viewed: 2/22/2023 11:26:19 AM Signed: 2/22/2023 11:26:34 AM
---	--	--

Electronic Record and Signature Disclosure:
Accepted: 7/20/2020 8:50:14 AM
ID: 5ebadf74-e399-40fd-be82-9c7ca902061b

In Person Signer Events	Signature	Timestamp
-------------------------	-----------	-----------

Editor Delivery Events	Status	Timestamp
------------------------	--------	-----------

Agent Delivery Events	Status	Timestamp
-----------------------	--------	-----------

Intermediary Delivery Events	Status	Timestamp
------------------------------	--------	-----------

Certified Delivery Events	Status	Timestamp
---------------------------	--------	-----------

Carbon Copy Events	Status	Timestamp
--------------------	--------	-----------

Witness Events	Signature	Timestamp
----------------	-----------	-----------

Notary Events	Signature	Timestamp
---------------	-----------	-----------

Envelope Summary Events	Status	Timestamps
-------------------------	--------	------------

Envelope Sent	Hashed/Encrypted	2/14/2023 9:48:53 AM
Certified Delivered	Security Checked	2/22/2023 11:26:19 AM
Signing Complete	Security Checked	2/22/2023 11:26:34 AM
Completed	Security Checked	2/22/2023 11:26:34 AM

Payment Events	Status	Timestamps
----------------	--------	------------

Electronic Record and Signature Disclosure
--

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, Insight OBO The Massachusetts General Hospital (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Insight OBO The Massachusetts General Hospital:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: jhenrique@mgh.harvard.edu

To advise Insight OBO The Massachusetts General Hospital of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at jhenrique@mgh.harvard.edu and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from Insight OBO The Massachusetts General Hospital

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to jhenrique@mgh.harvard.edu and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with Insight OBO The Massachusetts General Hospital

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an email to jhenrique@mgh.harvard.edu and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to ‘I agree to use electronic records and signatures’ before clicking ‘CONTINUE’ within the DocuSign system.

By selecting the check-box next to ‘I agree to use electronic records and signatures’, you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Insight OBO The Massachusetts General Hospital as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Insight OBO The Massachusetts General Hospital during the course of your relationship with Insight OBO The Massachusetts General Hospital.